Similarly, specific inhibitors of another m6A ‘eraser’, ALKBH5, have been tested and show efficient inhibition of GBM cell proliferation [102] enhanced radiosensitivity and reduced invasiveness of GSCs [103], and improved anti-PD1 treatment efficiency in a preclinical glioma model [104]. Here, ALKBH5 is linked to glioblastoma.